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Finding myself in my occasional roleas guest editor for this issue ofOncology News and it being the NCRI
supplement issue this month, I take the
opportunity of continuing a theme I
touched on in an editorial at about this
time last year, brought to mind by the
abstract of Prof Peter Selby’s invited
lecture on Clinical Research and
Healthcare Outcomes. Two statements
jogged my memory. Firstly, “The benefits
of clinical research have historically only
been available for a minority of patients”. Secondly
“Research active healthcare systems generate better
outcomes for patients”. He also mentions in the latter
context the notion, which he considers falls short of
convincing evidence, that individual patients in a
healthcare institution do better if included in
randomised trials.
My comment in the previous editorial was that
“This reductionism can build a parallel universe
where clinicians know well how best to treat patients
who would be eligible for an RCT, but arguably short
changes the many who would have been excluded”. I
have recently been following the fortunes of a good
friend who landed a job as a research nurse largely on
the basis of one multicentric, supranational clinical
trial. It is a cruel game I play with her that whenever
we meet I enquire whether she has managed to
recruit a patient yet. The fun might now be spoiled in
that most recently and after several months on the
job, a potential participant was apparently identified,
but not yet consented. It is not a rare cancer that is
involved here either: one of the top three, by
incidence, in fact.
The dilemma of choosing how far to go in designing
reductionist experiments, as against realistic ones, is
not the sole preserve of clinical trials researchers. It
pops up in the basic science research laboratory
where, for instance, those who work with primary
cultures tend to sniff at the rest of us who use cell
lines. They do so with reason, but not necessarily
with justification. Much of the biochemistry of life
was originally elucidated in micro-organisms. The
surprising conservation of genes through evolution
makes that possible. It tends to be the middle ground
where fine detail matters that causes controversy,
such as extrapolations from animal to man.
Stratifying drug development trials into four
phases, it is hard to knock phase I studies; tolerability
is an obvious first step as is dose escalation. Phase II
trials are usually small and loosely controlled, if at all;
adequate to identify some measure of efficacy.
Perhaps the minimal control element might however
be a bonus rather than a deficiency in
viewing the results. It is the climax of
the process with the phase III RCT
where the difficulties lie; in the
exertions to achieve homogeneous
groups so that only one variable (or as
near to one as possible) is up for
assessment. They do indeed supply
essential evidence, but evidence that
needs a sceptical reception. It is
perhaps for the statisticians and study
designers to seek the solutions, by
having the wherewithal and being happy to
deconvolute complex data and less inclined to insist
on relatively simplistic experimental designs with
rigid inclusion limits in order to ease interpretation. A
simple aid to gathering as much information as
possible is to follow the adage ‘randomise early,
stratify late’, even if that means excluding some
subsets from some analyses where they clearly do not
belong.
Phase IV, so called ongoing development, problem
identification and the emergence of extensions to the
original use is where a drug or protocol meets the real
world. Here I happily find myself singing from the
same hymn sheet as Prof Selby. The healthcare
system itself needs to be structurally research-minded
in order to supply much of that valuable Phase IV
data on which the development of real strategies for
real patients who could not be consented into a trial,
have an array of co-morbidities and inconvenient
staging or presentation of the cancer that constitutes
their most pressing problem. Or indeed cancer might
exist but not be the most pressing problem.
Clinical research meets investigative healthcare in
the realm of audit. This process combines elements of
research method with the quality control procedures
required of any organisation that is trying to deliver a
‘product’ of best quality to fulfil the legitimate and
reasonable expectations of the end user ... the patient,
that is, not the doctor or other healthcare practitioner.
So let us hope that the inevitable reorganisation of
both academia and the NHS will leave the former able
to provide valuable scientific input and the latter to
have the time space and money to keep clinical
research moving at the increasingly breakneck speed
required to keep up, both with those expectations and
the rest of the world. n
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